A primary challenge in gene therapy is ensuring the therapeutic gene is expressed:
(a) Continuously
(b) Only in target cells
(c) At the correct level
(d) All of the above
(a) Continuously
(b) Only in target cells
(c) At the correct level
(d) All of the above
Related Questions
Which of the following is NOT a common vector used in gene therapy?
Retrovirus
Adenovirus
Liposome
Bacteria
Which of the following techniques are not used for early diagnosis of a disease?
Genetic screening
Biomarker analysis
Palliative care
Medical imaging
Gene therapy for ADA deficiency involves modifying which type of cells?
Red blood cells
Platelets
White blood cells
Nerve cells
In gene therapy for Adenosine Deaminase (ADA) deficiency, repeated infusions of genetically engineered lymphocytes are required because:
Genetically engineered lymphocytes are not immortal and are periodically destroyed.
The introduced ADA gene is gradually silenced in the engineered lymphocytes.
The patient's immune system rejects the genetically engineered lymphocytes.
The genetically engineered lymphocytes migrate to other tissues and lose their functionality.
Which type of vector is used to introduce a functional ADA cDNA into lymphocytes, in gene therapy for ADA deficiency?
Plasmid
Bacteriophage
BAC
Retrovirus
The first clinical gene therapy was given in 1990 to a 4 years old girl with enzyme deficiency of
Monamine oxides
Tyrosine oxidase
Adenosine deaminase
Glutamate dehydrogenase
Adenosine Deaminase (ADA) deficiency can be cured by …A… and …B… but it is not fully curative. Here A and B can be
A-gene therapy, B-radiation therapy
A-bone marrow transplantation, B-enzyme replacement therapy
A-organ transplantation, B-hormone replacement therapy
A-radiation therapy, B-enzyme replacement therapy
The first clinical gene therapy was given in 1990 to a 4 years old girl with enzyme deficiency of
Monamine oxides
Tyrosine oxidase
Adenosine deaminase
Glutamate dehydrogenase
Which of the following could be a permanent cure for treatment of Severe Combined Immuno Deficiency (SCID)?
Gene therapy
Bone marrow transplant
Enzyme replacement therapy
All of the above
The site of the production of ADA in the body is
Bone marrow
Lymphocytes
Blood plasma
Monocytes
